[1] Rivera C.Essentials of oral cancer[J]. Int J Clin Exp Pathol, 2015, 8(9): 11884-11894. [2] He Q, Chen Z, Cabay RJ, et al.MicroRNA-21 and microRNA-375 from oral cytology as biomarkers for oral tongue cancer detection[J]. Oral Oncol, 2016, 57(1): 15-20. [3] Gu Y, Liu H, Kong F, et al.Mir-22 /KAT6B axis is a chemotherapeutic determiner via regulation of PI3k-Akt-NF-kB pathway in tongue squamous cell carcinoma[J]. J Exp Clin Cancer Res, 2018, 37(1): 164-177. [4] Schroeder GM, An Y, Cai ZW, et al.Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607),a selective and orally efficacious inhibitor of the Met kinase superfamily[J]. J Med Chem,2009, 52(5): 1251-1254. [5] Dai Y, Siemann DW.BMS-777607, a small-molecule Met kinase inhibitor,suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype[J]. Mol Cancer Ther, 2010, 9(6): 1554-1561. [6] Hu CY, Xu XM, Hong B, et al.Aberrant RON and MET co-overexpression as novel prognostic biomarkers of shortened patient survival and therapeutic targets of tyrosine kinase inhibitors in pancreatic cancer[J]. Front Oncol, 2019, 9: 1377-1392. [7] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1): 7-30. [8] Yu GT, Bu LL, Huang C, et al.PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma[J]. Oncotarget, 2015, 6(39): 42067-42080. [9] Yu X, Li Z.MicroRNA expression and its implications for diagnosis and therapy of tongue squamous cell carcinoma[J]. J Cell Mol Med, 2016, 20(1): 10-16. [10] Ko SY, Lin SC, Wong YK, et al.Increase of disintergin metalloprotease 10 (ADAM10) expression in oral squamous cell carcinoma[J]. Cancer Lett, 2007, 245(1-2): 33-43. [11] Chang K, Karnad A, Zhao S, et al.Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets[J]. Oncotarget, 2015, 6(6): 3507-3518. [12] Sharma S, Zeng ZJ, Zhuang CM, et al.Small-molecule inhibitor BMS-777607 induces breast cancer cell polyploidy with increased resistance to cytotoxic chemotherapy agents[J]. Mol Cancer Ther, 2013, 12(5): 725-736. [13] Very N, Vercoutter-Edouart AS, Lefebvre T, et al.Cross-dysregulation of O -GlcNAcylation and PI3K/AKT/mTOR axis in human chronic diseases[J]. Front Endocrinol (Lausanne), 2018, 9: 602-611. [14] McKinzie BP, Bulliington WM, Mazur JE, et al. Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations[J]. Am J Med Sci, 2010, 339(1): 1-4. [15] Faham N, Zhao L, Welm AL. mTORC1 is a key mediator of RON-dependent breast cancer metastasis with therapeutic potential[J]. NPJ Breast Cancer, 2018, 4(1): 641-650. [16] Ma JC,Sun XW,Su H,et al.Fibroblast-derived CXCL12/SDF-1α promotes CXCL6 secretion and co-operatively enhances metastatic potential through the PI3K/Akt/mTOR pathway in colon cancer[J].World J Gastroenterol, 2017, 23(28): 5167-5178. [17] 辛敏, 陈健, 郭艳红, 等. 异黄酮对膀胱癌细胞凋亡和PI3K/Akt信号通路的影响[J]. 广东医学, 2015, 36(5): 690-693. [18] Liu LS, Bai XQ, Gao Y, et al.PCSK9 promotes oxLDL-Induced PC12 cell apoptosis through the Bcl-2/Bax-Caspase 9/3 signaling pathway[J]. Alzheimers Dis, 2017, 57(3): 723-734. [19] Fulda S.Targeting apoptosis for anticancer therapy[J]. Semin Cancer Biol, 2015, 31(1): 84-88. [20] Derakhshan A, Chen Z, Van Waes C.Therapeutic small molecules target inhibitor of apoptosis proteins in cancers with deregulation of extrinsic and intrinsic cell death pathways[J]. Clin Cancer Res, 2017, 23(6): 1378-1387. |